<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Fam Cancer</journal-id>
      <journal-title>Familial Cancer</journal-title>
      <issn pub-type="ppub">1389-9600</issn>
      <issn pub-type="epub">1573-7292</issn>
      <publisher>
        <publisher-name>Springer Netherlands</publisher-name>
        <publisher-loc>Dordrecht</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">18046629</article-id>
      <article-id pub-id-type="pmc">2253650</article-id>
      <article-id pub-id-type="publisher-id">9172</article-id>
      <article-id pub-id-type="doi">10.1007/s10689-007-9172-6</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Hereditary diffuse gastric cancer: association with lobular breast cancer</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Schrader</surname>
            <given-names>Kasmintan A.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Masciari</surname>
            <given-names>Serena</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Boyd</surname>
            <given-names>Niki</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Wiyrick</surname>
            <given-names>Sara</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kaurah</surname>
            <given-names>Pardeep</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Senz</surname>
            <given-names>Janine</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Burke</surname>
            <given-names>Wylie</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lynch</surname>
            <given-names>Henry T.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Garber</surname>
            <given-names>Judy E.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name name-style="western">
            <surname>Huntsman</surname>
            <given-names>David G.</given-names>
          </name>
          <address>
            <phone>+1-604-8776000</phone>
            <fax>+1-604-8776089</fax>
            <email>dhuntsma@bccancer.bc.ca</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Department of Pathology and Laboratory Medicine, University of British Columbia, British Columbia Cancer Agency, 600 W 10th Avenue, Vancouver, BC Canada V5Z 1L3 </aff>
        <aff id="Aff2"><label>2</label>Hereditary Cancer Program, British Columbia Cancer Agency, Vancouver, BC Canada </aff>
        <aff id="Aff3"><label>3</label>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA USA </aff>
        <aff id="Aff4"><label>4</label>Departments of Neurology and Medicine, University of Washington, Seattle, WA USA </aff>
        <aff id="Aff5"><label>5</label>Department of Medical History and Ethics, University of Washington, Seattle, WA USA </aff>
        <aff id="Aff6"><label>6</label>Department of Preventive Medicine and Public Health, Creighton University School of Medicine, Omaha, NE USA </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>29</day>
        <month>11</month>
        <year>2007</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>3</month>
        <year>2008</year>
      </pub-date>
      <volume>7</volume>
      <issue>1</issue>
      <fpage>73</fpage>
      <lpage>82</lpage>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2007</copyright-statement>
      </permissions>
      <abstract>
        <p>Hereditary diffuse gastric cancer (HDGC) has been shown to be caused by germline mutations in the gene <italic>CDH1</italic> located at 16q22.1, which encodes the cell&#x2013;cell adhesion molecule, E-cadherin. Not only does loss of expression of E-cadherin account for the morphologic differences between intestinal and diffuse gastric cancer (DGC) variants, but it also appears to lead to distinct cellular features which appear to be common amongst related cancers that have been seen in the syndrome. As in most hereditary cancer syndromes, multiple organ sites may be commonly affected by cancer, in HDGC, lobular carcinoma of the breast (LBC) and possibly other organ sites have been shown to be associated with the familial cancer syndrome. Given the complexity of HDGC, not only with regard to the management of the DGC risk, but also with regard to the risk for other related cancers, such as LBC, a multi-disciplinary approach is needed for the management of individuals with known <italic>CDH1</italic> mutations.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Hereditary diffuse gastric cancer (HDGC)</kwd>
        <kwd>Diffuse gastric cancer</kwd>
        <kwd>E-cadherin mutation</kwd>
        <kwd><italic>CDH1</italic> mutation</kwd>
        <kwd>Lobular breast cancer</kwd>
        <kwd>Screening</kwd>
        <kwd>Prophylactic total gastrectomy</kwd>
      </kwd-group>
      <custom-meta-wrap>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer Science+Business Media B.V. 2008</meta-value>
        </custom-meta>
      </custom-meta-wrap>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p>Despite an overall decrease in the global incidence of gastric cancer (GC) [<xref ref-type="bibr" rid="CR1">1</xref>], the incidence of the subtype, diffuse gastric cancer (DGC) has remained stable and may even be increasing [<xref ref-type="bibr" rid="CR2">2</xref>]. Within the past ten years, germline mutations in <italic>CDH1</italic>, which encodes E-cadherin, have been found [<xref ref-type="bibr" rid="CR3">3</xref>] in over 50% of hereditary diffuse gastric cancer (HDGC) families with at least two cases of GC, with one diagnosed as DGC before the age of 50&#xA0;years [<xref ref-type="bibr" rid="CR4">4</xref>]. Within these HDGC families, we and others have noted an overrepresentation of lobular breast cancer (LBC) [<xref ref-type="bibr" rid="CR4">4</xref>&#x2013;<xref ref-type="bibr" rid="CR8">8</xref>]. This observation has led to efforts to determine whether or not <italic>CDH1</italic> is a breast cancer susceptibility gene, distinct from its gastric cancer risk. Recently our group has reported a novel germline <italic>CDH1</italic> truncating mutation (517insA) in an LBC family with no known history of GC [<xref ref-type="bibr" rid="CR9">9</xref>]. Within this review we report a germline <italic>CDH1</italic> mutation in a second family in which breast cancer is the predominant cancer diagnosis. The management of HDGC in all patients with a particular focus on the management of the breast cancer risk associated with germline <italic>CDH1</italic> mutations will be discussed.</p>
    </sec>
    <sec id="Sec2" sec-type="methods">
      <title>Methods</title>
      <p>The described family was referred to the ongoing HDGC study at the British Columbia Cancer Agency from a cancer genetics clinic in Seattle, WA, USA. Informed consent was obtained from the proband by the referring genetic counselor following ascertainment of a detailed cancer family history and appropriate genetic counseling prior to germline mutation testing. Our laboratory carried out the molecular genetic testing for the <italic>CDH1</italic> mutation on a research basis. Approval for the HDGC study is by the clinical research ethics board of the University of British Columbia.</p>
      <p>The proband (IV-4) was diagnosed with widely metastatic lobular breast cancer at age 53&#xA0;years (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>a). Her family, of European ancestry, had a history of breast cancer diagnoses occurring in an autosomal dominant fashion on the maternal side of the family where her mother, aunt, and first cousin developed breast cancer in their 50&#x2019;s. Due to her high-risk pedigree <italic>BRCA1</italic>, <italic>BRCA2</italic>, and <italic>PTEN</italic> genetic testing was undertaken and all were negative. <italic>CDH1</italic> testing was also pursued.
<fig id="Fig1"><label>Fig.&#xA0;1</label><caption><p>(<bold>a</bold>) Pedigree of family reported showing a predominance of breast cancer. (<bold>b</bold>) Sequence from family carrying 1565&#xA0;+&#xA0;1G&#x2192;A mutation</p></caption><graphic position="anchor" xlink:href="10689_2007_9172_Fig1_HTML" id="MO1"/></fig></p>
    </sec>
    <sec id="Sec3" sec-type="results">
      <title>Results</title>
      <p>All 16 exons were amplified for DHPLC analysis [<xref ref-type="bibr" rid="CR6">6</xref>]. For exon 10 of <italic>CDH1</italic>, the initial amplicon failed and was therefore analyzed by direct sequencing and thus revealed a donor splice site mutation, 1565&#xA0;+&#xA0;1G&#xA0;&gt;&#xA0;A (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>b). Due to its position at a donor splice site, this mutation is regarded as pathogenic [<xref ref-type="bibr" rid="CR10">10</xref>].</p>
      <p>The proband&#x2019;s sisters (IV-2 and IV-6) participated in all aspects of the proband&#x2019;s genetic consultation. They were appropriately concerned about their risk of breast cancer, but had not thought much about the possibility of getting gastric cancer until the <italic>CDH1</italic> mutation was found. IV-2 and IV-6 had predictive genetic testing for the <italic>CDH1</italic> mutation testing and both were found to be negative. Other family members are being informed about the availability of predictive genetic testing.</p>
    </sec>
    <sec id="Sec4" sec-type="discussion">
      <title>Discussion</title>
      <sec id="Sec5">
        <title>E-cadherin</title>
        <p><italic>CDH1</italic> (OMIM *192090), located on chromosome 16q22.1 encodes, E-cadherin, an epithelial transmembrane cell&#x2013;cell adhesion molecule and member of the cadherin superfamily of glycoproteins. In a zipper-like fashion, its extracellular domain forms calcium-dependent homodimers between the E-cadherin molecules of adjacent epithelial cells, to act as the primary mediator of epithelial cell adhesion at the adherens junction complex [<xref ref-type="bibr" rid="CR11">11</xref>]. Through interactions of its cytoplasmic tail with multiple signalling and structural molecules, such as the catenins, E-cadherin, maintains cellular adhesion and epithelial architecture with this link to the cytoskeleton. The cytoplasmic tail of E-cadherin directly associates with &#x3B2;-catenin and &#x3B3;-catenin which in turn binds to the f-actin microfilaments of the cytoskeleton, directly or through &#x3B1;-catenin [<xref ref-type="bibr" rid="CR12">12</xref>]. p120-catenin also associates with E-cadherin&#x2019;s cytoplasmic tail at a different site, the juxtamembrane domain, and acts to both strengthen the adhesion between cells and regulate cadherin membrane trafficking and degradation [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. E-cadherin is considered to have an invasion suppressor role, where decreased expression permits cells to dissociate from each other in order to migrate and invade [<xref ref-type="bibr" rid="CR15">15</xref>]. In cancers, this manifests as increased infiltrative and metastatic potential [<xref ref-type="bibr" rid="CR16">16</xref>]. E-cadherin is also thought to act as a tumour suppressor, potentially through its interaction with the multipurpose &#x3B2; -catenin molecule which is an effector of the WNT signalling pathway [<xref ref-type="bibr" rid="CR17">17</xref>]. Loss of E-cadherin can result in &#x3B2;-catenin release from the membrane and translocation to the nucleus where it complexes with Tcf/Lef-1 transcription factors to initiate transcription of WNT responsive genes [<xref ref-type="bibr" rid="CR18">18</xref>]. Activation of these genes have been implicated in tumourigenesis through the WNT signalling pathway as seen in adenomatous polyposis coli (APC) [<xref ref-type="bibr" rid="CR19">19</xref>]. In support of the role of E-cadherin as a tumour suppressor is the observation of abnormal or absent E-cadherin expression in precursor lesions of DGC and LBC, where the phenomenon is seen in in&#xA0;situ signet ring cell carcinomas found in prophylactic gastrectomy specimens from germline <italic>CDH1</italic> mutation carriers [<xref ref-type="bibr" rid="CR20">20</xref>] and the lobular carcinoma in&#xA0;situ lesions seen adjacent to invasive lobular breast cancers [<xref ref-type="bibr" rid="CR21">21</xref>]. These examples suggest that loss of E-cadherin is an early or even tumour-initiating event, however the actual molecular basis of such a potential role of E-cadherin in such cases is unknown.</p>
        <p>Inactivating <italic>CDH1</italic> mutations are found in 50% of sporadic DGCs [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>] and cluster between exons seven and nine [<xref ref-type="bibr" rid="CR11">11</xref>], in contrast with the low percentage of mutations seen in sporadic intestinal type GCs [<xref ref-type="bibr" rid="CR23">23</xref>]. Decreased expression of E-cadherin in DGCs may account for morphologic differences between intestinal and DGC variants [<xref ref-type="bibr" rid="CR24">24</xref>]. Unlike somatic <italic>CDH1</italic> mutations, germline mutations associated with DGC are distributed throughout the gene [<xref ref-type="bibr" rid="CR7">7</xref>] (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). In the cancers from individuals with <italic>CDH1</italic> mutations, <italic>CDH1</italic> acts as a classic tumour suppressor gene with loss of expression of the wildtype allele [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. In a single study of 6 hereditary DGC cancers, inactivation of the wild-type allele could be attributed to promoter hypermethylation in 5 (83%) of cases [<xref ref-type="bibr" rid="CR26">26</xref>]. This finding warrants verification in a larger cohort as abnormal promoter methylation in early cancers could potentially form the basis of a screening test.
<fig id="Fig2"><label>Fig.&#xA0;2</label><caption><p>DGC and LBC associated <italic>CDH1</italic> germline mutations. Mutations shown above <italic>CDH1</italic> gene schematic occur in families with DGC history and those below <italic>CDH1</italic> occur in families with an additional or exclusive LBC history. In addition to the known <italic>CDH1</italic> germline mutations compiled by Kaurah et&#xA0;al. [<xref ref-type="bibr" rid="CR4">4</xref>], the recent mutation in an LBC family [<xref ref-type="bibr" rid="CR9">9</xref>] and novel mutation from this paper are shown and identified below the symbol denoting mutation type. * Denotes the halfway point of the <italic>CDH1</italic> coding sequence (1324 or the start of exon 10)</p></caption><graphic position="anchor" xlink:href="10689_2007_9172_Fig2_HTML" id="MO2"/></fig></p>
      </sec>
      <sec id="Sec6">
        <title>Lobular breast cancer and diffuse gastric cancer: loss of E-cadherin</title>
        <p>Currently germline mutations in single genes account for approximately 5&#x2013;10% of breast cancer [<xref ref-type="bibr" rid="CR27">27</xref>]. High penetrance genes such as <italic>BRCA1</italic> and <italic>2</italic> account for 3&#x2013;8%, and <italic>TP53</italic> and <italic>PTEN</italic> as seen in Li-Fraumeni and Cowden syndrome together only account for &lt;0.1% of breast cancer diagnoses [<xref ref-type="bibr" rid="CR28">28</xref>]. Other medium and low penetrance genes such as <italic>CHK2</italic>, <italic>BRIP1</italic>, <italic>PALB2</italic> and <italic>ATM</italic> [<xref ref-type="bibr" rid="CR29">29</xref>&#x2013;<xref ref-type="bibr" rid="CR32">32</xref>] have been identified, however, there still remains a proportion of hereditary breast cancer not yet determined. LBC accounts for approximately 10% of all breast cancers compared to the other major histologic subtype, invasive ductal carcinoma (IDC) [<xref ref-type="bibr" rid="CR33">33</xref>]. Several factors suggest that LBC has a stronger hereditary basis relative to IDC, such as the higher frequency of bilateral disease [<xref ref-type="bibr" rid="CR33">33</xref>], and also where excess familiality of LBC has been observed in population studies [<xref ref-type="bibr" rid="CR34">34</xref>]. LBCs compose only 3% and 9% of the breast cancer tumour types seen in germline BRCA 1 and 2 mutation carriers, respectively [<xref ref-type="bibr" rid="CR35">35</xref>], illustrating that the genetic risk factors for the majority of cases are unaccounted for by these genes.</p>
        <p>The histology of LBC is characterized by infiltrative cancer cells which are isolated, highly dispersive and demonstrate a growth pattern with scattered and single files of tumor cells dispersed in stromal tissue [<xref ref-type="bibr" rid="CR36">36</xref>]. This pathologic appearance is remarkably similar to DGCs and both LBC and DGC demonstrate characteristic mucinous, signet ring cells. This is not unexpected as E-cadherin staining is absent in 85% of sporadic invasive LBC [<xref ref-type="bibr" rid="CR37">37</xref>] and somatic <italic>CDH1</italic> mutations have been identified in 56% of sporadic LBCs [<xref ref-type="bibr" rid="CR38">38</xref>]. Furthermore, in IDC, somatic <italic>CDH1</italic> mutations are not found [<xref ref-type="bibr" rid="CR38">38</xref>] and complete loss of E-cadherin expression is an uncommon feature. As loss of E-cadherin expression is a distinctive trait of both LBCs and DGCs, it likely contributes to the unique histopathologic features shared by the two cancers.</p>
        <p>There are some differences with regard to the nature of the mutations seen in LBC and DGC. Generally mutations associated with sporadic LBC have been found to be nonsense or frameshift mutations [<xref ref-type="bibr" rid="CR39">39</xref>] which encode truncated, non-functional proteins, whereas in sporadic DGC, mutations have generally been found to be splice site and in-frame mutations [<xref ref-type="bibr" rid="CR11">11</xref>]. In sporadic LBC, mutations in <italic>CDH1</italic> are spread throughout the gene [<xref ref-type="bibr" rid="CR11">11</xref>] compared with the mutations seen in sporadic DGC which tend to cluster. Germline <italic>CDH1</italic> mutations associated with DGC and/or LBC occur throughout the gene (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). However, when the DGC and LBC associated <italic>CDH1</italic> mutations are tabulated and compared based on their 3&#x2032; or 5&#x2032; positions relative to the halfway point of the <italic>CDH1</italic> coding sequence (1324 or the start of exon 10), LBC associated mutations show a statistically significant trend towards clustering at the 3&#x2032; end (Fisher&#x2019;s exact test, two-tailed <italic>P</italic>-value equals 0.0467) (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). As this association is of weak statistical significance, it is unlikely to impact clinical testing strategies. Future analyses of novel germline LBC<italic>-</italic>associated <italic>CDH1</italic> mutations should help to confirm this observation. Another difference between the molecular genetics of the two types of cancers, is that in sporadic LBC, silencing of E-cadherin expression is generally accomplished by a mutation in one allele in combination with loss of heterozygosity (LOH) or promoter hypermethylation in the remaining allele [<xref ref-type="bibr" rid="CR40">40</xref>]. This is in contrast to sporadic DGC, where biallellic inactivation is achieved by mutations in one allele in concert with promoter hypermethylation in the other [<xref ref-type="bibr" rid="CR41">41</xref>].</p>
        <p>We have recently identified a truncating germline <italic>CDH1</italic> mutation in an LBC family where analysis of the tumour was suggestive of partial LOH in the WT allele [<xref ref-type="bibr" rid="CR9">9</xref>]. Our current case demonstrates a germline <italic>CDH1</italic> mutation (1565&#xA0;+&#xA0;1G&#xA0;&gt;&#xA0;A) in a predominantly breast cancer family, which is predicted to disrupt splicing. The mutation is in the same conserved position as a previously reported mutation (1565&#xA0;+&#xA0;1G&#xA0;&gt;&#xA0;T) which was found in an Arabian HDGC family with no recorded history of breast cancer [<xref ref-type="bibr" rid="CR42">42</xref>]. Moreover, a previous study reported a germline missense mutation in a proband with LBC but did not detail family history, or functionally characterize the missense mutation [<xref ref-type="bibr" rid="CR43">43</xref>]. These examples demonstrate the need for further studies of germline mutations in LBC families in order to determine the mutation frequency and potential genotype-phenotype correlations.</p>
      </sec>
      <sec id="Sec7">
        <title>Lobular breast cancer and HDGC</title>
        <p>Breast cancer has been observed in HDGC kindreds to the extent where clustering of LBCs within HDGC families has led to the misclassification of families as breast cancer kindreds who test negative for <italic>BRCA1</italic>/<italic>2</italic> mutations [<xref ref-type="bibr" rid="CR4">4</xref>]. In 1998, Keller described the first case of histologically defined LBC in association with HDGC [<xref ref-type="bibr" rid="CR5">5</xref>]. Since then, several more HDGC families with associated breast cancer were reported where it was observed, that these cases were LBCs when pathology was available [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR6">6</xref>&#x2013;<xref ref-type="bibr" rid="CR8">8</xref>].</p>
        <p>Prior to establishment of the association between HDGC and LBC, several efforts to determine whether <italic>CDH1</italic> was a breast cancer susceptibility gene were attempted in view of the well-recognised phenotype of loss of E-cadherin expression displayed by the breast cancer subtype. For various reasons these studies failed to demonstrate the link. Rahman et&#xA0;al. examined 65 cases of lobular carcinoma in&#xA0;situ, however did not pre-screen the cases based on family history and included a wide age range, from 26 to 71&#xA0;years, not necessarily in keeping with the usual age of onset seen in hereditary cancer syndromes [<xref ref-type="bibr" rid="CR44">44</xref>]. Salashor examined 19 breast cancer tumours exhibiting LOH at the <italic>CDH1</italic> locus, however of those, only 3 were confirmed to be pure LBC or mixed LBC/IDC pathology [<xref ref-type="bibr" rid="CR45">45</xref>]. Lei examined 13 familial LBC cases and found no mutations, however did not define the extent of the family history [<xref ref-type="bibr" rid="CR46">46</xref>].</p>
        <p>Penetrance data based on 11 HDGC families, estimated the cumulative risk for LBC for female mutation carriers to be 39% (95% CI, 12&#x2013;84%) by 80&#xA0;years of age [<xref ref-type="bibr" rid="CR47">47</xref>]. More recently we have published an estimated cumulative risk for breast cancer for females by the age of 75&#xA0;years as being 52% (95% CI, 29&#x2013;94%) from analysis of 4 predominantly gastric cancer pedigrees from Newfoundland with the 2398delC <italic>CDH1</italic> founder mutation [<xref ref-type="bibr" rid="CR4">4</xref>]. This is with the caveat that LBC risk for <italic>CDH1</italic> mutation carriers has been assessed within high risk HDGC families, leading to a potential ascertainment bias and underestimation of the role of <italic>CDH1</italic> mutations in LBC development. To accommodate for this we have begun analysis of <italic>CDH1</italic> mutations within familial lobular breast cancer families or those families ascertained through a relatively young index case with confirmed LBC and have found germline <italic>CDH1</italic> mutations in these kindreds [<xref ref-type="bibr" rid="CR9">9</xref>].</p>
      </sec>
      <sec id="Sec8">
        <title>Clinical implications of <italic>CDH1</italic> associated LBC risk</title>
        <p>At this time, it seems reasonable to conclude that at least four groups of women are at increased risk for LBC: women with LBC and a family history of breast cancer, women with a known <italic>CDH1</italic> mutation, women from families with diffuse gastric cancer in whom no <italic>CDH1</italic> mutation has yet been identified; and women with a germline <italic>BRCA2</italic> mutation. Since there has not yet been a large population based study of the prevalence of <italic>CDH1</italic> mutations among women with lobular breast cancer, it is premature to recommend genetic evaluation to women with a family history of breast cancer unless, at the very least, one of the breast cancers can be shown to have been lobular. Additional research can be expected to provide better guidance for these families.</p>
        <p>Although there are not yet definitive data available on surveillance or risk reduction programs for women with known <italic>CDH1</italic> mutations or untested women from <italic>CDH1</italic>-positive families, the high lifetime risk of LBC (39&#x2013;52%) [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR47">47</xref>] that these women face mandates their careful management. We suggest that they follow the recommendations for other high-risk women with hereditary breast cancer predisposition. This subgroup should be advised to practice breast self-examination; and to have annual mammograms, and semiannual clinical breast examination, beginning at least by age 30. There is certainly interest in regular bilateral breast MRI, as lobular breast cancer are known to frequently elude mammographic detection because they do not form masses or develop calcifications. These women can also be counseled to consider hormonal chemoprevention, since most LBCs are estrogen receptor positive [<xref ref-type="bibr" rid="CR33">33</xref>], and both tamoxifen and raloxifene reduce the risk of estrogen receptor positive [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>] breast cancers in randomized trials. In addition, the risk reduction was greatest with both agents in women with lobular carcinoma in&#xA0;situ [<xref ref-type="bibr" rid="CR50">50</xref>].</p>
        <p>Prophylactic mastectomy may also be considered an option by some <italic>CDH1</italic>-positive women, particularly those who have been previously diagnosed with breast cancer in one breast or those who have had to undergo multiple biopsies for abnormal clinical findings. Several studies have reported a 90% reduction in breast cancer incidence with prophylactic mastectomy among women with a strong family history or with a germline BRCA1 or BRCA2 mutation [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. The published series include some lobular breast cancers, but not at numbers sufficient to permit meaningful subset analysis at this time.</p>
      </sec>
      <sec id="Sec9">
        <title>Management of hereditary diffuse gastric cancer</title>
        <p>Penetrance studies examining data from HDGC families, have estimated the lifetime risk of developing gastric cancer by age 75 and 80 respectively, to be from 40&#x2013;67% in men, to 63&#x2013;83% in women [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. Although identification of germline <italic>CDH1</italic> mutations has enabled a significant proportion of HDGC families to utilise predictive testing to determine their individual risks of GC within <italic>CDH1</italic> mutation positive pedigrees, unfortunately screening for DGC is ineffective and the current recommendation is for consideration of prophylactic gastrectomy in mutation positive individuals. Positron emission tomography [<xref ref-type="bibr" rid="CR53">53</xref>] and chromoendoscopic-directed biopsies [<xref ref-type="bibr" rid="CR54">54</xref>] have been proposed over basic endoscopy as more sensitive means of screening carriers, however screening methods have been consistently undermined by the recurrent discovery of multifocal DGC lesions underlying normal mucosa in prophylactic gastrectomy specimens of individuals with recent negative screening [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]. Regardless of the current limitations of screening, it is currently recommended that consideration for genetic testing and screening begin in at risk individuals in the late teens or early twenties [<xref ref-type="bibr" rid="CR4">4</xref>] and that prophylactic total gastrectomy be considered in the early twenties for mutation carriers. Female mutation carriers will need specialized counseling to the potential nutritional effects on pregnancy following gastrectomy [<xref ref-type="bibr" rid="CR57">57</xref>]. Further studies are currently underway to examine the quality of life impact of prophylactic gastrectomies. In the case report herein, although there was a GC in the maternal grandfather, the family history was more striking for the large number of breast cancer cases. This highlights the particular challenges we currently face with regard to counseling these families which appear to be mainly breast cancer, as it is unknown if the penetrance of DGC in this family is as high as it is in other HDGC pedigrees.</p>
      </sec>
    </sec>
    <sec id="Sec10" sec-type="conclusion">
      <title>Conclusion</title>
      <p>HDGC is one of a number of hereditary cancer syndromes that feature both an increased breast and gastric cancer risk (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). In general, a lack of shared genetic risks for most breast and GI cancers was suggested through a recent study of 13,023 genes in 11 breast and 11 colon cancer cell lines in which the only commonly mutated gene between these two cancer types is <italic>p53</italic> [<xref ref-type="bibr" rid="CR58">58</xref>]. This likely reflects underlying differences in the biology of these diseases, however also highlights the unique nature of germline mutations in the <italic>CDH1</italic> gene which are strongly associated with specific histologically defined subtypes of breast and GI cancer, namely LBC and DGC which are both part of the HDGC syndrome.
<table-wrap id="Tab1"><label>Table&#xA0;1</label><caption><p>Other syndromes with familial susceptibility to breast and gastric cancers</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Syndrome</th><th align="left">Mode of inheritance</th><th align="left">Associated gene(s)</th><th align="left">Sites of primary cancer(s)</th><th align="left">Evidence for association with the syndrome </th></tr></thead><tbody><tr><td align="left">BRCA2 Hereditary Breast/Ovarian Cancer</td><td align="left">AD</td><td align="left"><italic>BRCA2</italic></td><td align="left">Breast<break/>Ovary<break/>Larynx<break/>Prostate</td><td align="left">BC is considered an integral tumor of the syndrome with an average cumulative risk in carriers by age 70 years of 45% (95% confidence interval (CI) 31&#x2013;56%) [<xref ref-type="bibr" rid="CR59">59</xref>]<break/>Familial aggregations of both BC and GC have been reported [<xref ref-type="bibr" rid="CR60">60</xref>]<break/>In a study of 173 families, relative risk for GC was 2.6 [<xref ref-type="bibr" rid="CR61">61</xref>]<break/>Among Ashkenazi Jewish GC patients, the frequency of 617delT mutation is five times that of the general Ashkenazi Jewish population frequency [<xref ref-type="bibr" rid="CR62">62</xref>] <break/>Among other cancers, GC occurred in first degree relatives when mutations were located in the ovarian cancer cluster region of exon 11 of <italic>BRCA2</italic> [<xref ref-type="bibr" rid="CR63">63</xref>] </td></tr><tr><td align="left">BRCA1 Hereditary Breast/Ovarian Cancer</td><td align="left">AD</td><td align="left"><italic>BRCA1</italic></td><td align="left">Breast<break/>Ovary <break/>Prostate</td><td align="left">BC is considered an integral tumor of the syndrome with an average cumulative risk in carriers by age 70 years of 72.8% (95% confidence interval [CI]&#xA0;=&#xA0;67.9% to 77.7%) [<xref ref-type="bibr" rid="CR64">64</xref>]<break/>There is a 4 times increased risk for GC [<xref ref-type="bibr" rid="CR64">64</xref>]</td></tr><tr><td align="left">Peutz-Jeghers Syndrome</td><td align="left">AD</td><td align="left"><italic>STK 11</italic></td><td align="left">Gastrointestinal (GI) tract</td><td align="left">GC is considered an integral tumor of the syndrome with a relative risk of 213 (95% confidence interval 96&#x2013;368) [<xref ref-type="bibr" rid="CR65">65</xref>] <break/>BC is considered an integral tumor of the syndrome with a relative risk of 15.2 (95% CI 7.6&#x2013;27) [<xref ref-type="bibr" rid="CR65">65</xref>] </td></tr><tr><td align="left">Cowden Syndrome</td><td align="left">AD</td><td align="left"><italic>PTEN</italic></td><td align="left">Breast<break/>Thyroid<break/>Endometrium</td><td align="left">BC is considered an integral tumor of the syndrome with an incidence of 22&#x2013;50% [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR67">67</xref>]<break/>GC in&#xA0;situ has been reported in a patient with Cowden Syndrome [<xref ref-type="bibr" rid="CR68">68</xref>]</td></tr><tr><td align="left">Li-Fraumeni Syndrome</td><td align="left">AD</td><td align="left"><italic>TP53</italic><break/><italic>CHK2</italic></td><td align="left">Breast<break/>Adrenal cortex<break/>Connective tissue<break/>Kidney<break/>Nervous system<break/>Pancreas <break/>White blood cells</td><td align="left">BC is frequently found in families with this cancer susceptibility syndrome [<xref ref-type="bibr" rid="CR69">69</xref>]<break/>Chompret expanded the spectrum of cancers to include GC [<xref ref-type="bibr" rid="CR70">70</xref>]<break/>Germline <italic>TP53</italic> mutations have been found in GC families without <italic>CDH1</italic> mutations [<xref ref-type="bibr" rid="CR71">71</xref>&#x2013;<xref ref-type="bibr" rid="CR73">73</xref>]<break/>The 1100delC <italic>CHK2</italic> allele confers a 2.2 fold risk of BC to carriers [<xref ref-type="bibr" rid="CR29">29</xref>], however germline mutations in GC kindreds have not been identified [<xref ref-type="bibr" rid="CR74">74</xref>]</td></tr><tr><td align="left">Familial Adenomatous Polyposis</td><td align="left">AD</td><td align="left"><italic>APC</italic></td><td align="left">Colon and rectum<break/>Duodenum<break/>Thyroid<break/>Pancreas</td><td align="left">Literature review by Shimoyama et&#xA0;al. totalled 30 reported cases of GC and FAP [<xref ref-type="bibr" rid="CR76">76</xref>]<break/>47% to 49% of primary BCs had promoter hypermethylation at the <italic>APC</italic> locus [<xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR78">78</xref>]<break/>23% of LBCs have been shown to have LOH of <italic>APC</italic> [<xref ref-type="bibr" rid="CR43">43</xref>]</td></tr><tr><td align="left">Lynch Syndrome (Hereditary Nonpolyposis Colon Cancer (HNPCC))</td><td align="left">AD</td><td align="left"><italic>hMSH2</italic><break/><italic>hMLH1</italic><break/><italic>hMSH6</italic><break/><italic>hPMS1</italic><break/><italic>hPMS2</italic></td><td align="left">Colon and rectum<break/>Endometrium<break/>Stomach <break/>Small intestine<break/>Urothelium<break/>Kidney<break/>Ovary<break/>Skin<break/>Pancreas<break/>Brain<break/>White blood cells <break/>Biliary tract</td><td align="left">Gastric cancer accounted for 5% of cancers in families harboring <italic>MLH1</italic> or <italic>MSH2</italic> mutations [<xref ref-type="bibr" rid="CR76">76</xref>]<break/><italic>hMLH1</italic> mutations in large kindred segregated with BCs exhibiting microsatellite instability (MSI) [<xref ref-type="bibr" rid="CR79">79</xref>]<break/>A slight increased incidence of BC was seen in <italic>hMLH1</italic> mutation carriers [<xref ref-type="bibr" rid="CR80">80</xref>]<break/>Germline <italic>hMSH2</italic> mutation carrier with BC exhibited LOH for <italic>hMSH2</italic> in tumors analyzed [<xref ref-type="bibr" rid="CR81">81</xref>]<break/>Analysis of primary invasive BCs demonstrated that 25% of tumours were immunonegative for MSH2 staining [<xref ref-type="bibr" rid="CR82">82</xref>]</td></tr><tr><td align="left">&#xA0;Ataxia-telangiectasia (AT)</td><td align="left">AR</td><td align="left"><italic>ATM</italic></td><td align="left">White blood cells</td><td align="left">Mutations causing AT in homozygotes, confer susceptibility to BC in heterozygotes, where women with <italic>ATM</italic> mutations have a &#x223C;2-fold risk of BC and &#x223C;15% of these women will develop the disease [<xref ref-type="bibr" rid="CR32">32</xref>]<break/>GC has been reported in association with the syndrome [<xref ref-type="bibr" rid="CR83">83</xref>&#x2013;<xref ref-type="bibr" rid="CR85">85</xref>]<break/>There is evidence of excess risks of GC in heterozygotes (RR&#xA0;=&#xA0;3.39, 95% CI&#xA0;=&#xA0;0.86 to 13.4) [<xref ref-type="bibr" rid="CR86">86</xref>]</td></tr><tr><td align="left">Xeroderma pigmentosum</td><td align="left">AR</td><td align="left"><italic>XPA</italic><break/><italic>ERCC3 (XPB)</italic><break/><italic>XPC</italic><break/><italic>ERCC2(XPD)</italic><break/><italic>DDB2(XPE)</italic><break/><italic>ERCC4(XPF)</italic><break/><italic>ERCC5(XPG)</italic><break/><italic>POLH(XP-V)</italic></td><td align="left">Skin<break/>Eyes</td><td align="left">BC and GC have both independently been reported with the syndrome [<xref ref-type="bibr" rid="CR87">87</xref>,<xref ref-type="bibr" rid="CR88">88</xref>]</td></tr><tr><td align="left">Werner Syndrome</td><td align="left">AR</td><td align="left"><italic>WRN</italic></td><td align="left">Connective tissue <break/>Skin<break/>Thyroid</td><td align="left">GC has been reported in association with the syndrome [<xref ref-type="bibr" rid="CR89">89</xref>] <break/>There are no reports of BC in association with Werner syndrome. Although, there is evidence supporting <italic>WRN</italic> as a low-penetrance familial BC susceptibility gene, where patients harboring both <italic>WRN</italic> Cys1367Arg or <italic>TP53</italic> MspI variants had an increased BC risk (OR&#xA0;=&#xA0;3.39, 95% CI 1.19&#x2013;9.71) [<xref ref-type="bibr" rid="CR90">90</xref>] </td></tr></tbody></table><table-wrap-foot><p>AD&#xA0;=&#xA0;autosomal dominant, AR&#xA0;=&#xA0;autosomal recessive</p></table-wrap-foot></table-wrap></p>
      <p>With the recent demonstration of a <italic>CDH1</italic> mutation in a family ascertained through an index case of LBC and in view of the additional new mutation in a predominantly breast cancer family that we have described here, the evidence for establishing LBC as part of the HDGC syndrome is strong. There now is a need for establishing the prevalence of <italic>CDH1</italic> mutations in LBC families to avoid the ascertainment bias generated from only looking at cases from families identified because of their family history of GC. It is not currently known what the risk of GC is in these families which present predominantly as having a susceptibility to breast cancer and therefore identification of <italic>CDH1</italic> as a true susceptibility gene for LBC could result in <italic>CDH1</italic> screening and effective risk reduction strategies for selected breast cancer families and further studies examining their risk for gastric and other cancers.</p>
      <p>Most hereditary cancer syndromes are associated with cancer risk involving multiple organs. Here we have discussed germline <italic>CDH1</italic> mutations and the risks with regard to DGC and LBC, however as the recognised spectrum of related cancers broadens, more affected families will be identified and successfully managed with regard to avoidance of specific cancer risks. Longer life expectancy in individuals with penetrant mutations could potentially lead to the development of different, later onset disease as yet to be identified in these kindreds. This represents a particular challenge in hereditary cancer practice as the clinical community tends to be segregated into organ specific specialties where as the cancer risks and the risk reduction strategies for germline mutation carriers require a variety of expertise. The medical needs of the HDGC families are therefore best served through an engaged multidisciplinary team.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgements</title>
      <p>This work was supported in part by the National Cancer Institute of Canada (NCIC) and the British Columbia/Yukon Territory chapter of the Canadian Breast Cancer Foundation. DGH is a Michael Smith Foundation for Health Research Senior Scholar.</p>
      <p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Crew</surname>
              <given-names>KD</given-names>
            </name>
            <name>
              <surname>Neugut</surname>
              <given-names>AI</given-names>
            </name>
          </person-group>
          <article-title>Epidemiology of gastric cancer</article-title>
          <source>World J Gastroenterol</source>
          <year>2006</year>
          <volume>3</volume>
          <fpage>354</fpage>
          <lpage>362</lpage>
        </citation>
        <citation citation-type="display-unstructured">Crew KD, Neugut AI (2006) Epidemiology of gastric cancer. World J Gastroenterol 3:354&#x2013;362 <pub-id pub-id-type="pmid">16489633</pub-id></citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Henson</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Dittus</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Younes</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973&#x2013;2000: increase in the signet ring cell type</article-title>
          <source>Arch Pathol Lab Med</source>
          <year>2004</year>
          <volume>7</volume>
          <fpage>765</fpage>
          <lpage>770</lpage>
        </citation>
        <citation citation-type="display-unstructured">Henson DE, Dittus C, Younes M et&#xA0;al (2004) Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973&#x2013;2000: increase in the signet ring cell type. Arch Pathol Lab Med 7:765&#x2013;770 <pub-id pub-id-type="pmid">15214826</pub-id></citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Guilford</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Hopkins</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Harraway</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>E-cadherin germline mutations in familial gastric cancer</article-title>
          <source>Nature</source>
          <year>1998</year>
          <volume>6674</volume>
          <fpage>402</fpage>
          <lpage>405</lpage>
          <pub-id pub-id-type="doi">10.1038/32918</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Guilford P, Hopkins J, Harraway J et&#xA0;al (1998) E-cadherin germline mutations in familial gastric cancer. Nature 6674:402&#x2013;405 <pub-id pub-id-type="pmid">9537325</pub-id></citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaurah</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>MacMillan</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Boyd</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer</article-title>
          <source>JAMA</source>
          <year>2007</year>
          <volume>21</volume>
          <fpage>2360</fpage>
          <lpage>2372</lpage>
          <pub-id pub-id-type="doi">10.1001/jama.297.21.2360</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kaurah P, MacMillan A., Boyd N et&#xA0;al (2007) Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA 21:2360&#x2013;2372 <pub-id pub-id-type="pmid">17545690</pub-id></citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Keller</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Vogelsang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Becker</surname>
              <given-names>I</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation</article-title>
          <source>Am J Pathol</source>
          <year>1999</year>
          <volume>2</volume>
          <fpage>337</fpage>
          <lpage>342</lpage>
        </citation>
        <citation citation-type="display-unstructured">Keller G, Vogelsang H, Becker I et&#xA0;al (1999) Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol 2:337&#x2013;342 <pub-id pub-id-type="pmid">10433926</pub-id></citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Suriano</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Yew</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ferreira</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management</article-title>
          <source>Clin Cancer Res</source>
          <year>2005</year>
          <volume>15</volume>
          <fpage>5401</fpage>
          <lpage>5409</lpage>
          <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-0247</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Suriano G, Yew S, Ferreira P et&#xA0;al (2005) Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management. Clin Cancer Res 15:5401&#x2013;5409 <pub-id pub-id-type="pmid">16061854</pub-id></citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oliveira</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bordin</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Grehan</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred</article-title>
          <source>Hum Mutat</source>
          <year>2002</year>
          <volume>5</volume>
          <fpage>510</fpage>
          <lpage>517</lpage>
          <pub-id pub-id-type="doi">10.1002/humu.10068</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Oliveira C, Bordin MC, Grehan N et&#xA0;al (2002) Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. Hum Mutat 5:510&#x2013;517 <pub-id pub-id-type="pmid">11968083</pub-id></citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brooks-Wilson</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Kaurah</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Suriano</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria</article-title>
          <source>J Med Genet</source>
          <year>2004</year>
          <volume>7</volume>
          <fpage>508</fpage>
          <lpage>517</lpage>
          <pub-id pub-id-type="doi">10.1136/jmg.2004.018275</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Brooks-Wilson AR, Kaurah P, Suriano G et&#xA0;al (2004) Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet 7:508&#x2013;517 <pub-id pub-id-type="pmid">15235021</pub-id></citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Masciari</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Larsson</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Senz</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Germline E-Cadherin mutations in familial lobular breast cancer</article-title>
          <source>J Med Genet</source>
          <year>2007</year>
          <volume>44</volume>
          <fpage>726</fpage>
          <lpage>731</lpage>
          <pub-id pub-id-type="doi">10.1136/jmg.2007.051268</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Masciari S, Larsson N, Senz J et&#xA0;al (2007) Germline E-Cadherin mutations in familial lobular breast cancer. J Med Genet 44:726&#x2013;731 <pub-id pub-id-type="pmid">17660459</pub-id></citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Graziano</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Humar</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Guilford</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice</article-title>
          <source>Ann Oncol</source>
          <year>2003</year>
          <volume>12</volume>
          <fpage>1705</fpage>
          <lpage>1713</lpage>
          <pub-id pub-id-type="doi">10.1093/annonc/mdg486</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Graziano F, Humar B, Guilford P (2003) The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice. Ann Oncol 12:1705&#x2013;1713 <pub-id pub-id-type="pmid">14630673</pub-id></citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Berx</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Becker</surname>
              <given-names>KF</given-names>
            </name>
            <name>
              <surname>Hofler</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutations of the human E-cadherin (CDH1) gene</article-title>
          <source>Hum Mutat</source>
          <year>1998</year>
          <volume>4</volume>
          <fpage>226</fpage>
          <lpage>237</lpage>
          <pub-id pub-id-type="doi">10.1002/(SICI)1098-1004(1998)12:4&lt;226::AID-HUMU2&gt;3.0.CO;2-D</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Berx G, Becker KF, Hofler H et&#xA0;al (1998) Mutations of the human E-cadherin (CDH1) gene. Hum Mutat 4:226&#x2013;237 <pub-id pub-id-type="pmid">9744472</pub-id></citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aberle</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Schwartz</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kemler</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Cadherin-catenin complex: protein interactions and their implications for cadherin function</article-title>
          <source>J Cell Biochem</source>
          <year>1996</year>
          <volume>4</volume>
          <fpage>514</fpage>
          <lpage>523</lpage>
          <pub-id pub-id-type="doi">10.1002/(SICI)1097-4644(19960616)61:4&lt;514::AID-JCB4&gt;3.0.CO;2-R</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Aberle H, Schwartz H, Kemler R (1996) Cadherin-catenin complex: protein interactions and their implications for cadherin function. J Cell Biochem 4:514&#x2013;523 <pub-id pub-id-type="pmid">8806074</pub-id></citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thoreson</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Anastasiadis</surname>
              <given-names>PZ</given-names>
            </name>
            <name>
              <surname>Daniel</surname>
              <given-names>JM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Selective uncoupling of p120(ctn) from E-cadherin disrupts strong adhesion</article-title>
          <source>J Cell Biol</source>
          <year>2000</year>
          <volume>1</volume>
          <fpage>189</fpage>
          <lpage>202</lpage>
          <pub-id pub-id-type="doi">10.1083/jcb.148.1.189</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Thoreson MA, Anastasiadis PZ, Daniel JM et&#xA0;al (2000) Selective uncoupling of p120(ctn) from E-cadherin disrupts strong adhesion. J Cell Biol 1:189&#x2013;202 <pub-id pub-id-type="pmid">10629228</pub-id></citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xiao</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Oas</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Chiasson</surname>
              <given-names>CM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Role of p120-catenin in cadherin trafficking</article-title>
          <source>Biochim Biophys Acta</source>
          <year>2007</year>
          <volume>1</volume>
          <fpage>8</fpage>
          <lpage>16</lpage>
        </citation>
        <citation citation-type="display-unstructured">Xiao K, Oas RG, Chiasson CM et&#xA0;al (2007) Role of p120-catenin in cadherin trafficking. Biochim Biophys Acta 1:8&#x2013;16 <pub-id pub-id-type="pmid">16949165</pub-id></citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vleminckx</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Vakaet</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Mareel</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role</article-title>
          <source>Cell</source>
          <year>1991</year>
          <volume>1</volume>
          <fpage>107</fpage>
          <lpage>119</lpage>
          <pub-id pub-id-type="doi">10.1016/0092-8674(91)90143-M</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Vleminckx K, Vakaet L Jr, Mareel M et&#xA0;al (1991) Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1:107&#x2013;119 <pub-id pub-id-type="pmid">2070412</pub-id></citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wijnhoven</surname>
              <given-names>BP</given-names>
            </name>
            <name>
              <surname>Dinjens</surname>
              <given-names>WN</given-names>
            </name>
            <name>
              <surname>Pignatelli</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>E-cadherin-catenin cell&#x2013;cell adhesion complex and human cancer</article-title>
          <source>Br J Surg</source>
          <year>2000</year>
          <volume>8</volume>
          <fpage>992</fpage>
          <lpage>1005</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2168.2000.01513.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Wijnhoven BP, Dinjens WN, Pignatelli M (2000) E-cadherin-catenin cell&#x2013;cell adhesion complex and human cancer. Br J Surg 8:992&#x2013;1005 <pub-id pub-id-type="pmid">10931041</pub-id></citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Novak</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Dedhar</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Signaling through beta-catenin and Lef/Tcf</article-title>
          <source>Cell Mol Life Sci</source>
          <year>1999</year>
          <volume>5&#x2013;6</volume>
          <fpage>523</fpage>
          <lpage>537</lpage>
        </citation>
        <citation citation-type="display-unstructured">Novak A, Dedhar S (1999) Signaling through beta-catenin and Lef/Tcf. Cell Mol Life Sci 5&#x2013;6:523&#x2013;537 </citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Orsulic</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Huber</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Aberle</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>E-cadherin binding prevents beta-catenin nuclear localization and beta-catenin/LEF-1-mediated transactivation</article-title>
          <source>J Cell Sci</source>
          <year>1999</year>
          <volume>Pt 8</volume>
          <fpage>1237</fpage>
          <lpage>1245</lpage>
        </citation>
        <citation citation-type="display-unstructured">Orsulic S, Huber O, Aberle H et&#xA0;al (1999) E-cadherin binding prevents beta-catenin nuclear localization and beta-catenin/LEF-1-mediated transactivation. J Cell Sci Pt 8:1237&#x2013;1245 <pub-id pub-id-type="pmid">10085258</pub-id></citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aoki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Taketo</surname>
              <given-names>MM</given-names>
            </name>
          </person-group>
          <article-title>Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene</article-title>
          <source>J Cell Sci</source>
          <year>2007</year>
          <volume>Pt 19</volume>
          <fpage>3327</fpage>
          <lpage>3335</lpage>
          <pub-id pub-id-type="doi">10.1242/jcs.03485</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Aoki K, Taketo MM (2007) Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene. J Cell Sci Pt 19:3327&#x2013;3335 <pub-id pub-id-type="pmid">17881494</pub-id></citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carneiro</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Huntsman</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Smyrk</surname>
              <given-names>TC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening</article-title>
          <source>J Pathol</source>
          <year>2004</year>
          <volume>2</volume>
          <fpage>681</fpage>
          <lpage>687</lpage>
          <pub-id pub-id-type="doi">10.1002/path.1564</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Carneiro F, Huntsman DG, Smyrk TC et&#xA0;al (2004) Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol 2:681&#x2013;687 <pub-id pub-id-type="pmid">15141383</pub-id></citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leeuw</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Berx</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Vos</surname>
              <given-names>CB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in&#xA0;situ</article-title>
          <source>J Pathol</source>
          <year>1997</year>
          <volume>4</volume>
          <fpage>404</fpage>
          <lpage>411</lpage>
          <pub-id pub-id-type="doi">10.1002/(SICI)1096-9896(199712)183:4&lt;404::AID-PATH1148&gt;3.0.CO;2-9</pub-id>
        </citation>
        <citation citation-type="display-unstructured">De Leeuw WJ, Berx G, Vos CB et&#xA0;al (1997) Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in&#xA0;situ. J Pathol 4:404&#x2013;411 <pub-id pub-id-type="pmid">9496256</pub-id></citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Becker</surname>
              <given-names>KF</given-names>
            </name>
            <name>
              <surname>Atkinson</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Reich</surname>
              <given-names>U</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>E-cadherin gene mutations provide clues to diffuse type gastric carcinomas</article-title>
          <source>Cancer Res</source>
          <year>1994</year>
          <volume>14</volume>
          <fpage>3845</fpage>
          <lpage>3852</lpage>
        </citation>
        <citation citation-type="display-unstructured">Becker KF, Atkinson MJ, Reich U et&#xA0;al (1994) E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 14:3845&#x2013;3852 <pub-id pub-id-type="pmid">8033105</pub-id></citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Becker</surname>
              <given-names>KF</given-names>
            </name>
            <name>
              <surname>Hofler</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Frequent somatic allelic inactivation of the E-cadherin gene in gastric carcinomas</article-title>
          <source>J Natl Cancer Inst</source>
          <year>1995</year>
          <volume>14</volume>
          <fpage>1082</fpage>
          <lpage>1084</lpage>
          <pub-id pub-id-type="doi">10.1093/jnci/87.14.1082</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Becker KF, Hofler H (1995) Frequent somatic allelic inactivation of the E-cadherin gene in gastric carcinomas. J Natl Cancer Inst 14:1082&#x2013;1084 <pub-id pub-id-type="pmid">7616601</pub-id></citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Machado</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Soares</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Carneiro</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>E-cadherin gene mutations provide a genetic basis for the phenotypic divergence of mixed gastric carcinomas</article-title>
          <source>Lab Invest</source>
          <year>1999</year>
          <volume>79</volume>
          <fpage>459</fpage>
          <lpage>465</lpage>
        </citation>
        <citation citation-type="display-unstructured">Machado JC, Soares P, Carneiro F et&#xA0;al (1999) E-cadherin gene mutations provide a genetic basis for the phenotypic divergence of mixed gastric carcinomas. Lab Invest 79:459&#x2013;465 <pub-id pub-id-type="pmid">10211998</pub-id></citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <citation citation-type="other">Carneiro F, Oliveira C, Suriano G et&#xA0;al (2007) Molecular pathology of familial gastric cancer. J. Clin. Pathol</citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grady</surname>
              <given-names>WM</given-names>
            </name>
            <name>
              <surname>Willis</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Guilford</surname>
              <given-names>PJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer</article-title>
          <source>Nat Genet</source>
          <year>2000</year>
          <volume>1</volume>
          <fpage>16</fpage>
          <lpage>17</lpage>
        </citation>
        <citation citation-type="display-unstructured">Grady WM, Willis J, Guilford PJ et&#xA0;al (2000) Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet 1:16&#x2013;17 <pub-id pub-id-type="pmid">10973239</pub-id></citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thull</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Vogel</surname>
              <given-names>VG</given-names>
            </name>
          </person-group>
          <article-title>Recognition and management of hereditary breast cancer syndromes</article-title>
          <source>Oncologist</source>
          <year>2004</year>
          <volume>1</volume>
          <fpage>13</fpage>
          <lpage>24</lpage>
          <pub-id pub-id-type="doi">10.1634/theoncologist.9-1-13</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Thull DL, Vogel VG (2004) Recognition and management of hereditary breast cancer syndromes. Oncologist 1:13&#x2013;24 <pub-id pub-id-type="pmid">14755011</pub-id></citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rosman</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Kaklamani</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Pasche</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>New insights into breast cancer genetics and impact on patient management</article-title>
          <source>Curr Treat Options Oncol</source>
          <year>2007</year>
          <volume>1</volume>
          <fpage>61</fpage>
          <lpage>73</lpage>
          <pub-id pub-id-type="doi">10.1007/s11864-007-0021-5</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Rosman DS, Kaklamani V, Pasche B (2007) New insights into breast cancer genetics and impact on patient management. Curr Treat Options Oncol 1:61&#x2013;73 <pub-id pub-id-type="pmid">17634833</pub-id></citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <collab>CHEK2 Breast Cancer Case-Control Consortium</collab>
          </person-group>
          <article-title>CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies</article-title>
          <source>Am J Hum Genet</source>
          <year>2004</year>
          <volume>6</volume>
          <fpage>1175</fpage>
          <lpage>1182</lpage>
          <pub-id pub-id-type="doi">10.1086/421251</pub-id>
        </citation>
        <citation citation-type="display-unstructured">CHEK2 Breast Cancer Case-Control Consortium (2004) CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 6:1175&#x2013;1182 </citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Seal</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Renwick</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles</article-title>
          <source>Nat Genet</source>
          <year>2006</year>
          <volume>11</volume>
          <fpage>1239</fpage>
          <lpage>1241</lpage>
          <pub-id pub-id-type="doi">10.1038/ng1902</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Seal S, Thompson D, Renwick A et&#xA0;al (2006) Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 11:1239&#x2013;1241 <pub-id pub-id-type="pmid">17033622</pub-id></citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rahman</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Seal</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene</article-title>
          <source>Nat Genet</source>
          <year>2007</year>
          <volume>2</volume>
          <fpage>165</fpage>
          <lpage>167</lpage>
          <pub-id pub-id-type="doi">10.1038/ng1959</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Rahman N, Seal S, Thompson D et&#xA0;al (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 2:165&#x2013;167 <pub-id pub-id-type="pmid">17200668</pub-id></citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ahmed</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rahman</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>ATM and breast cancer susceptibility</article-title>
          <source>Oncogene</source>
          <year>2006</year>
          <volume>43</volume>
          <fpage>5906</fpage>
          <lpage>5911</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.onc.1209873</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Ahmed M, Rahman N (2006) ATM and breast cancer susceptibility. Oncogene 43:5906&#x2013;5911 <pub-id pub-id-type="pmid">16998505</pub-id></citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arpino</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bardou</surname>
              <given-names>VJ</given-names>
            </name>
            <name>
              <surname>Clark</surname>
              <given-names>GM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome</article-title>
          <source>Breast Cancer Res</source>
          <year>2004</year>
          <volume>3</volume>
          <fpage>R149</fpage>
          <lpage>156</lpage>
          <pub-id pub-id-type="doi">10.1186/bcr767</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Arpino G, Bardou VJ, Clark GM et&#xA0;al (2004) Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 3:R149&#x2013;156 <pub-id pub-id-type="pmid">15084238</pub-id></citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Allen-Brady</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Camp</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Ward</surname>
              <given-names>JH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Lobular breast cancer: excess familiality observed in the Utah Population Database</article-title>
          <source>Int J Cancer</source>
          <year>2005</year>
          <volume>4</volume>
          <fpage>655</fpage>
          <lpage>661</lpage>
          <pub-id pub-id-type="doi">10.1002/ijc.21236</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Allen-Brady K, Camp NJ, Ward JH et&#xA0;al (2005) Lobular breast cancer: excess familiality observed in the Utah Population Database. Int J Cancer 4:655&#x2013;661 <pub-id pub-id-type="pmid">15929077</pub-id></citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lakhani</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Gusterson</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Jacquemier</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2</article-title>
          <source>Clin Cancer Res</source>
          <year>2000</year>
          <volume>3</volume>
          <fpage>782</fpage>
          <lpage>789</lpage>
        </citation>
        <citation citation-type="display-unstructured">Lakhani SR, Gusterson BA, Jacquemier J et&#xA0;al (2000) The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res 3:782&#x2013;789 <pub-id pub-id-type="pmid">10741697</pub-id></citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moll</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mitze</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Frixen</surname>
              <given-names>UH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas</article-title>
          <source>Am J Pathol</source>
          <year>1993</year>
          <volume>6</volume>
          <fpage>1731</fpage>
          <lpage>1742</lpage>
        </citation>
        <citation citation-type="display-unstructured">Moll R, Mitze M, Frixen UH et&#xA0;al (1993) Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am J Pathol 6:1731&#x2013;1742 <pub-id pub-id-type="pmid">8256859</pub-id></citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Berx</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Roy</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression</article-title>
          <source>Breast Cancer Res</source>
          <year>2001</year>
          <volume>5</volume>
          <fpage>289</fpage>
          <lpage>293</lpage>
          <pub-id pub-id-type="doi">10.1186/bcr309</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Berx G, Van Roy F (2001) The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res 5:289&#x2013;293 <pub-id pub-id-type="pmid">11597316</pub-id></citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Berx</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cleton-Jansen</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Strumane</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain</article-title>
          <source>Oncogene</source>
          <year>1996</year>
          <volume>9</volume>
          <fpage>1919</fpage>
          <lpage>1925</lpage>
        </citation>
        <citation citation-type="display-unstructured">Berx G, Cleton-Jansen AM, Strumane K et&#xA0;al (1996) E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene 9:1919&#x2013;1925 <pub-id pub-id-type="pmid">8934538</pub-id></citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Berx</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cleton-Jansen</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Nollet</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers</article-title>
          <source>EMBO J</source>
          <year>1995</year>
          <volume>24</volume>
          <fpage>6107</fpage>
          <lpage>6115</lpage>
        </citation>
        <citation citation-type="display-unstructured">Berx G, Cleton-Jansen AM, Nollet F et&#xA0;al (1995) E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J 24:6107&#x2013;6115 <pub-id pub-id-type="pmid">8557030</pub-id></citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Droufakou</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Deshmane</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Roylance</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast</article-title>
          <source>Int J Cancer</source>
          <year>2001</year>
          <volume>3</volume>
          <fpage>404</fpage>
          <lpage>408</lpage>
          <pub-id pub-id-type="doi">10.1002/ijc.1208</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Droufakou S, Deshmane V, Roylance R et&#xA0;al (2001) Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int J Cancer 3:404&#x2013;408 <pub-id pub-id-type="pmid">11291078</pub-id></citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Machado</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Carvalho</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma</article-title>
          <source>Oncogene</source>
          <year>2001</year>
          <volume>12</volume>
          <fpage>1525</fpage>
          <lpage>1528</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.onc.1204234</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Machado JC, Oliveira C, Carvalho R et&#xA0;al (2001) E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene 12:1525&#x2013;1528 <pub-id pub-id-type="pmid">11313896</pub-id></citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Humar</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Toro</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Graziano</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Novel germline CDH1 mutations in hereditary diffuse gastric cancer families</article-title>
          <source>Hum Mutat</source>
          <year>2002</year>
          <volume>5</volume>
          <fpage>518</fpage>
          <lpage>525</lpage>
          <pub-id pub-id-type="doi">10.1002/humu.10067</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Humar B, Toro T, Graziano F et&#xA0;al (2002) Novel germline CDH1 mutations in hereditary diffuse gastric cancer families. Hum Mutat 5:518&#x2013;525 <pub-id pub-id-type="pmid">11968084</pub-id></citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sarrio</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Moreno-Bueno</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Hardisson</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability</article-title>
          <source>Int J Cancer</source>
          <year>2003</year>
          <volume>2</volume>
          <fpage>208</fpage>
          <lpage>215</lpage>
          <pub-id pub-id-type="doi">10.1002/ijc.11197</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Sarrio D, Moreno-Bueno G, Hardisson D et&#xA0;al (2003) Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. Int J Cancer 2:208&#x2013;215 <pub-id pub-id-type="pmid">12800196</pub-id></citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rahman</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Stone</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Coleman</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Lobular carcinoma in&#xA0;situ of the breast is not caused by constitutional mutations in the E-cadherin gene</article-title>
          <source>Br J Cancer</source>
          <year>2000</year>
          <volume>3</volume>
          <fpage>568</fpage>
          <lpage>570</lpage>
        </citation>
        <citation citation-type="display-unstructured">Rahman N, Stone JG, Coleman G et&#xA0;al (2000) Lobular carcinoma in&#xA0;situ of the breast is not caused by constitutional mutations in the E-cadherin gene. Br J Cancer 3:568&#x2013;570 <pub-id pub-id-type="pmid">10682667</pub-id></citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Salahshor</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Haixin</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Huo</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Low frequency of E-cadherin alterations in familial breast cancer</article-title>
          <source>Breast Cancer Res</source>
          <year>2001</year>
          <volume>3</volume>
          <fpage>199</fpage>
          <lpage>207</lpage>
          <pub-id pub-id-type="doi">10.1186/bcr295</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Salahshor S, Haixin L, Huo H et&#xA0;al (2001) Low frequency of E-cadherin alterations in familial breast cancer. Breast Cancer Res 3:199&#x2013;207 <pub-id pub-id-type="pmid">11305955</pub-id></citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lei</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Sjoberg-Margolin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Salahshor</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>CDH1 mutations are present in both ductal and lobular breast cancer, but promoter allelic variants show no detectable breast cancer risk</article-title>
          <source>Int J Cancer</source>
          <year>2002</year>
          <volume>2</volume>
          <fpage>199</fpage>
          <lpage>204</lpage>
          <pub-id pub-id-type="doi">10.1002/ijc.10176</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Lei H, Sjoberg-Margolin S, Salahshor S et&#xA0;al (2002) CDH1 mutations are present in both ductal and lobular breast cancer, but promoter allelic variants show no detectable breast cancer risk. Int J Cancer 2:199&#x2013;204 <pub-id pub-id-type="pmid">11857408</pub-id></citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pharoah</surname>
              <given-names>PD</given-names>
            </name>
            <name>
              <surname>Guilford</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Caldas</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families</article-title>
          <source>Gastroenterology</source>
          <year>2001</year>
          <volume>6</volume>
          <fpage>1348</fpage>
          <lpage>1353</lpage>
          <pub-id pub-id-type="doi">10.1053/gast.2001.29611</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Pharoah PD, Guilford P, Caldas C et&#xA0;al (2001) Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 6:1348&#x2013;1353 <pub-id pub-id-type="pmid">11729114</pub-id></citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fisher</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Costantino</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Redmond</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors</article-title>
          <source>N Engl J Med</source>
          <year>1989</year>
          <volume>8</volume>
          <fpage>479</fpage>
          <lpage>484</lpage>
        </citation>
        <citation citation-type="display-unstructured">Fisher B, Costantino J, Redmond C et&#xA0;al (1989) A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 8:479&#x2013;484 <pub-id pub-id-type="pmid">2644532</pub-id></citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Land</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Wickerham</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Costantino</surname>
              <given-names>JP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial</article-title>
          <source>JAMA</source>
          <year>2006</year>
          <volume>23</volume>
          <fpage>2742</fpage>
          <lpage>2751</lpage>
          <pub-id pub-id-type="doi">10.1001/jama.295.23.joc60075</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Land SR, Wickerham DL, Costantino JP et&#xA0;al (2006) Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 23:2742&#x2013;2751 <pub-id pub-id-type="pmid">16754728</pub-id></citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <citation citation-type="other">Wolmark N, Dunn BK (2001) The role of tamoxifen in breast cancer prevention: issues sparked by the NSABP Breast Cancer Prevention Trial (P-1). Ann NY Acad Sci 99&#x2013;108</citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rebbeck</surname>
              <given-names>TR</given-names>
            </name>
            <name>
              <surname>Friebel</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Lynch</surname>
              <given-names>HT</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group</article-title>
          <source>J Clin Oncol</source>
          <year>2004</year>
          <volume>6</volume>
          <fpage>1055</fpage>
          <lpage>1062</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2004.04.188</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Rebbeck TR, Friebel T, Lynch HT et&#xA0;al (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 6:1055&#x2013;1062 <pub-id pub-id-type="pmid">14981104</pub-id></citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Robson</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Svahn</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>McCormick</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series</article-title>
          <source>Cancer</source>
          <year>2005</year>
          <volume>1</volume>
          <fpage>44</fpage>
          <lpage>51</lpage>
          <pub-id pub-id-type="doi">10.1002/cncr.20728</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Robson M, Svahn T, McCormick B et&#xA0;al (2005) Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series. Cancer 1:44&#x2013;51 <pub-id pub-id-type="pmid">15558796</pub-id></citation>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kouwen</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Drenth</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Oye</surname>
              <given-names>WJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>[18F]Fluoro-2-deoxy-<sc>d</sc>-glucose positron emission tomography detects gastric carcinoma in an early stage in an asymptomatic E-cadherin mutation carrier</article-title>
          <source>Clin Cancer Res</source>
          <year>2004</year>
          <volume>19</volume>
          <fpage>6456</fpage>
          <lpage>6459</lpage>
          <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-0599</pub-id>
        </citation>
        <citation citation-type="display-unstructured">van Kouwen MC, Drenth JP, Oye WJ et&#xA0;al (2004) [18F]Fluoro-2-deoxy-d-glucose positron emission tomography detects gastric carcinoma in an early stage in an asymptomatic E-cadherin mutation carrier. Clin Cancer Res 19:6456&#x2013;6459 <pub-id pub-id-type="pmid">15475432</pub-id></citation>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shaw</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Blair</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Framp</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Chromoendoscopic surveillance in hereditary diffuse gastric cancer: an alternative to prophylactic gastrectomy?</article-title>
          <source>Gut</source>
          <year>2005</year>
          <volume>4</volume>
          <fpage>461</fpage>
          <lpage>468</lpage>
          <pub-id pub-id-type="doi">10.1136/gut.2004.049171</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Shaw D, Blair V, Framp A et&#xA0;al (2005) Chromoendoscopic surveillance in hereditary diffuse gastric cancer: an alternative to prophylactic gastrectomy? Gut 4:461&#x2013;468 <pub-id pub-id-type="pmid">15753528</pub-id></citation>
      </ref>
      <ref id="CR55">
        <label>55.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huntsman</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Carneiro</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Lewis</surname>
              <given-names>FR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations</article-title>
          <source>N Engl J Med</source>
          <year>2001</year>
          <volume>25</volume>
          <fpage>1904</fpage>
          <lpage>1909</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJM200106213442504</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Huntsman DG, Carneiro F, Lewis FR et&#xA0;al (2001) Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med 25:1904&#x2013;1909 <pub-id pub-id-type="pmid">11419427</pub-id></citation>
      </ref>
      <ref id="CR56">
        <label>56.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Norton</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Ham</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Dam</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer</article-title>
          <source>Ann Surg</source>
          <year>2007</year>
          <volume>6</volume>
          <fpage>873</fpage>
          <lpage>879</lpage>
          <pub-id pub-id-type="doi">10.1097/01.sla.0000254370.29893.e4</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Norton JA, Ham CM, Van Dam J et&#xA0;al (2007) CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 6:873&#x2013;879 <pub-id pub-id-type="pmid">17522512</pub-id></citation>
      </ref>
      <ref id="CR57">
        <label>57.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lynch</surname>
              <given-names>HT</given-names>
            </name>
            <name>
              <surname>Grady</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Suriano</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Gastric cancer: new genetic developments</article-title>
          <source>J Surg Oncol</source>
          <year>2005</year>
          <volume>3</volume>
          <fpage>114</fpage>
          <lpage>133</lpage>
          <pub-id pub-id-type="doi">10.1002/jso.20214</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Lynch HT, Grady W, Suriano G et&#xA0;al (2005) Gastric cancer: new genetic developments. J Surg Oncol 3:114&#x2013;133; discussion 133 <pub-id pub-id-type="pmid">15895459</pub-id></citation>
      </ref>
      <ref id="CR58">
        <label>58.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sjoblom</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wood</surname>
              <given-names>LD</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The consensus coding sequences of human breast and colorectal cancers</article-title>
          <source>Science</source>
          <year>2006</year>
          <volume>5797</volume>
          <fpage>268</fpage>
          <lpage>274</lpage>
          <pub-id pub-id-type="doi">10.1126/science.1133427</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Sjoblom T, Jones S, Wood LD et&#xA0;al (2006) The consensus coding sequences of human breast and colorectal cancers. Science 5797:268&#x2013;274 <pub-id pub-id-type="pmid">16959974</pub-id></citation>
      </ref>
      <ref id="CR59">
        <label>59.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Antoniou</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pharoah</surname>
              <given-names>PD</given-names>
            </name>
            <name>
              <surname>Narod</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies</article-title>
          <source>Am J Hum Genet</source>
          <year>2003</year>
          <volume>5</volume>
          <fpage>1117</fpage>
          <lpage>1130</lpage>
          <pub-id pub-id-type="doi">10.1086/375033</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Antoniou A, Pharoah PD, Narod S et&#xA0;al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 5:1117&#x2013;1130 <pub-id pub-id-type="pmid">12677558</pub-id></citation>
      </ref>
      <ref id="CR60">
        <label>60.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jakubowska</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nej</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Huzarski</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>BRCA2 gene mutations in families with aggregations of breast and stomach cancers</article-title>
          <source>Br J Cancer</source>
          <year>2002</year>
          <volume>8</volume>
          <fpage>888</fpage>
          <lpage>891</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.bjc.6600562</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Jakubowska A, Nej K, Huzarski T et&#xA0;al (2002) BRCA2 gene mutations in families with aggregations of breast and stomach cancers. Br J Cancer 8:888&#x2013;891 <pub-id pub-id-type="pmid">12373604</pub-id></citation>
      </ref>
      <ref id="CR61">
        <label>61.</label>
        <citation citation-type="other">Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium (1999) J Natl Cancer Inst 15:1310&#x2013;1316</citation>
      </ref>
      <ref id="CR62">
        <label>62.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Figer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Irmin</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Geva</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel</article-title>
          <source>Br J Cancer</source>
          <year>2001</year>
          <volume>4</volume>
          <fpage>478</fpage>
          <lpage>481</lpage>
          <pub-id pub-id-type="doi">10.1054/bjoc.2000.1605</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Figer A, Irmin L, Geva R et&#xA0;al (2001) The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel. Br J Cancer 4:478&#x2013;481 <pub-id pub-id-type="pmid">11207041</pub-id></citation>
      </ref>
      <ref id="CR63">
        <label>63.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Risch</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>McLaughlin</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Cole</surname>
              <given-names>DE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer</article-title>
          <source>Am J Hum Genet</source>
          <year>2001</year>
          <volume>3</volume>
          <fpage>700</fpage>
          <lpage>710</lpage>
          <pub-id pub-id-type="doi">10.1086/318787</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Risch HA, McLaughlin JR, Cole DE et&#xA0;al (2001) Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 3:700&#x2013;710 <pub-id pub-id-type="pmid">11179017</pub-id></citation>
      </ref>
      <ref id="CR64">
        <label>64.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brose</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Rebbeck</surname>
              <given-names>TR</given-names>
            </name>
            <name>
              <surname>Calzone</surname>
              <given-names>KA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program</article-title>
          <source>J Natl Cancer Inst</source>
          <year>2002</year>
          <volume>18</volume>
          <fpage>1365</fpage>
          <lpage>1372</lpage>
        </citation>
        <citation citation-type="display-unstructured">Brose MS, Rebbeck TR, Calzone KA et&#xA0;al (2002) Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 18:1365&#x2013;1372 <pub-id pub-id-type="pmid">12237282</pub-id></citation>
      </ref>
      <ref id="CR65">
        <label>65.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Giardiello</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Brensinger</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Tersmette</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Goodman</surname>
              <given-names>SN</given-names>
            </name>
            <name>
              <surname>Petersen</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Booker</surname>
              <given-names>SV</given-names>
            </name>
            <name>
              <surname>Cruz-Correa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Offerhaus</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Very high risk of cancer in familial Peutz-Jeghers syndrome</article-title>
          <source>Gastroenterology</source>
          <year>2000</year>
          <volume>6</volume>
          <fpage>1447</fpage>
          <lpage>1453</lpage>
          <pub-id pub-id-type="doi">10.1053/gast.2000.20228</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM, Booker SV, Cruz-Correa M, Offerhaus JA (2000) Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 6:1447&#x2013;1453 <pub-id pub-id-type="pmid">11113065</pub-id></citation>
      </ref>
      <ref id="CR66">
        <label>66.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Starink</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Veen</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Arwert</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The Cowden syndrome: a clinical and genetic study in 21 patients</article-title>
          <source>Clin Genet</source>
          <year>1986</year>
          <volume>3</volume>
          <fpage>222</fpage>
          <lpage>233</lpage>
        </citation>
        <citation citation-type="display-unstructured">Starink TM, van der Veen JP, Arwert F et&#xA0;al (1986) The Cowden syndrome: a clinical and genetic study in 21 patients. Clin Genet 3:222&#x2013;233 <pub-id pub-id-type="pmid">3698331</pub-id></citation>
      </ref>
      <ref id="CR67">
        <label>67.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brownstein</surname>
              <given-names>M.H.</given-names>
            </name>
            <name>
              <surname>Wolf</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Bikowski</surname>
              <given-names>J.B</given-names>
            </name>
          </person-group>
          <article-title>Cowden&#x2019;s disease: a cutaneous marker of breast cancer</article-title>
          <source>Cancer</source>
          <year>1978</year>
          <volume>6</volume>
          <fpage>2393</fpage>
          <lpage>2398</lpage>
          <pub-id pub-id-type="doi">10.1002/1097-0142(197806)41:6&lt;2393::AID-CNCR2820410644&gt;3.0.CO;2-K</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Brownstein M.H., Wolf M., Bikowski J.B. (1978) Cowden&#x2019;s disease: a cutaneous marker of breast cancer. Cancer 6:2393&#x2013;2398 <pub-id pub-id-type="pmid">657103</pub-id></citation>
      </ref>
      <ref id="CR68">
        <label>68.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hamby</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>EY</given-names>
            </name>
            <name>
              <surname>Schwartz</surname>
              <given-names>RW</given-names>
            </name>
          </person-group>
          <article-title>Parathyroid adenoma and gastric carcinoma as manifestations of Cowden&#x2019;s disease</article-title>
          <source>Surgery</source>
          <year>1995</year>
          <volume>1</volume>
          <fpage>115</fpage>
          <lpage>117</lpage>
          <pub-id pub-id-type="doi">10.1016/S0039-6060(05)80018-2</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Hamby LS, Lee EY, Schwartz RW (1995) Parathyroid adenoma and gastric carcinoma as manifestations of Cowden&#x2019;s disease. Surgery 1:115&#x2013;117 <pub-id pub-id-type="pmid">7604372</pub-id></citation>
      </ref>
      <ref id="CR69">
        <label>69.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Birch</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Alston</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>McNally</surname>
              <given-names>RJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Relative frequency and morphology of cancers in carriers of germline TP53 mutations</article-title>
          <source>Oncogene</source>
          <year>2001</year>
          <volume>34</volume>
          <fpage>4621</fpage>
          <lpage>4628</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.onc.1204621</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Birch JM, Alston RD, McNally RJ et&#xA0;al (2001) Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 34:4621&#x2013;4628 <pub-id pub-id-type="pmid">11498785</pub-id></citation>
      </ref>
      <ref id="CR70">
        <label>70.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chompret</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Abel</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Stoppa-Lyonnet</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Sensitivity and predictive value of criteria for p53 germline mutation screening</article-title>
          <source>J Med Genet</source>
          <year>2001</year>
          <volume>1</volume>
          <fpage>43</fpage>
          <lpage>47</lpage>
          <pub-id pub-id-type="doi">10.1136/jmg.38.1.43</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Chompret A, Abel A, Stoppa-Lyonnet D et&#xA0;al (2001) Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet 1:43&#x2013;47 <pub-id pub-id-type="pmid">11332399</pub-id></citation>
      </ref>
      <ref id="CR71">
        <label>71.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Keller</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Vogelsang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Becker</surname>
              <given-names>I</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Germline mutations of the E-cadherin(CDH1) and TP53 genes, rather than of RUNX3 and HPP1:contribute to genetic predisposition in German gastric cancer patients</article-title>
          <source>J Med Genet</source>
          <year>2004</year>
          <volume>6</volume>
          <fpage>e89</fpage>
          <pub-id pub-id-type="doi">10.1136/jmg.2003.015594</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Keller G, Vogelsang H, Becker I et&#xA0;al (2004) Germline mutations of the E-cadherin(CDH1) and TP53 genes, rather than of RUNX3 and HPP1:contribute to genetic predisposition in German gastric cancer patients. J Med Genet 6:e89 <pub-id pub-id-type="pmid">15173255</pub-id></citation>
      </ref>
      <ref id="CR72">
        <label>72.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>IJ</given-names>
            </name>
            <name>
              <surname>Kang</surname>
              <given-names>HC</given-names>
            </name>
            <name>
              <surname>Shin</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A TP53-truncating germline mutation (E287X) in a family with characteristics of both hereditary diffuse gastric cancer and Li-Fraumeni syndrome</article-title>
          <source>J Hum Genet</source>
          <year>2004</year>
          <volume>49</volume>
          <fpage>591</fpage>
          <lpage>595</lpage>
          <pub-id pub-id-type="doi">10.1007/s10038-004-0193-9</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kim IJ, Kang HC, Shin Y et&#xA0;al (2004) A TP53-truncating germline mutation (E287X) in a family with characteristics of both hereditary diffuse gastric cancer and Li-Fraumeni syndrome. J Hum Genet 49:591&#x2013;595 <pub-id pub-id-type="pmid">15368100</pub-id></citation>
      </ref>
      <ref id="CR73">
        <label>73.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oliveira</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ferreira</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Nabais</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>E-Cadherin (CDH1) and p53 rather than SMAD4 and Caspase-10 germline mutations contribute to genetic predisposition in Portuguese gastric cancer patients</article-title>
          <source>Eur J Cancer</source>
          <year>2004</year>
          <volume>12</volume>
          <fpage>1897</fpage>
          <lpage>1903</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejca.2004.04.027</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Oliveira C, Ferreira P, Nabais S et&#xA0;al (2004) E-Cadherin (CDH1) and p53 rather than SMAD4 and Caspase-10 germline mutations contribute to genetic predisposition in Portuguese gastric cancer patients. Eur J Cancer 12:1897&#x2013;1903 <pub-id pub-id-type="pmid">15288293</pub-id></citation>
      </ref>
      <ref id="CR74">
        <label>74.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kimura</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Shinmura</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yoshimura</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Absence of germline CHK2 mutations in familial gastric cancer</article-title>
          <source>Jpn J Cancer Res</source>
          <year>2000</year>
          <volume>9</volume>
          <fpage>875</fpage>
          <lpage>879</lpage>
        </citation>
        <citation citation-type="display-unstructured">Kimura K, Shinmura K, Yoshimura K et&#xA0;al (2000) Absence of germline CHK2 mutations in familial gastric cancer. Jpn J Cancer Res 9:875&#x2013;879 <pub-id pub-id-type="pmid">11011113</pub-id></citation>
      </ref>
      <ref id="CR75">
        <label>75.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shimoyama</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Aoki</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Kawahara</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Early gastric cancer development in a familial adenomatous polyposis patient</article-title>
          <source>Dig Dis Sci</source>
          <year>2004</year>
          <volume>2</volume>
          <fpage>260</fpage>
          <lpage>265</lpage>
          <pub-id pub-id-type="doi">10.1023/B:DDAS.0000017448.58196.dc</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Shimoyama S, Aoki F, Kawahara M et&#xA0;al (2004) Early gastric cancer development in a familial adenomatous polyposis patient. Dig Dis Sci 2:260&#x2013;265 <pub-id pub-id-type="pmid">15104367</pub-id></citation>
      </ref>
      <ref id="CR76">
        <label>76.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dulaimi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Hillinck</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ibanez Caceres</surname>
              <given-names>I</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients</article-title>
          <source>Clin Cancer Res</source>
          <year>2004</year>
          <volume>18</volume>
          <issue>Pt 1</issue>
          <fpage>6189</fpage>
          <lpage>6193</lpage>
          <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-0597</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Dulaimi E, Hillinck J, Ibanez de Caceres I et&#xA0;al (2004) Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin Cancer Res 18(Pt 1):6189&#x2013;6193 <pub-id pub-id-type="pmid">15448006</pub-id></citation>
      </ref>
      <ref id="CR77">
        <label>77.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shinozaki</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hoon</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Giuliano</surname>
              <given-names>AE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis</article-title>
          <source>Clin Cancer Res</source>
          <year>2005</year>
          <volume>6</volume>
          <fpage>2156</fpage>
          <lpage>2162</lpage>
          <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-1810</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Shinozaki M, Hoon DS, Giuliano AE et&#xA0;al (2005) Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin Cancer Res 6:2156&#x2013;2162 <pub-id pub-id-type="pmid">15788661</pub-id></citation>
      </ref>
      <ref id="CR78">
        <label>78.</label>
        <citation citation-type="other">Geary J, Sasieni P, Houlston R et&#xA0;al (2007) Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). Fam Cancer</citation>
      </ref>
      <ref id="CR79">
        <label>79.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Risinger</surname>
              <given-names>JI</given-names>
            </name>
            <name>
              <surname>Barrett</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Watson</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Molecular genetic evidence of the occurrence of breast cancer as an integral tumor in patients with the hereditary nonpolyposis colorectal carcinoma syndrome</article-title>
          <source>Cancer</source>
          <year>1996</year>
          <volume>9</volume>
          <fpage>1836</fpage>
          <lpage>1843</lpage>
          <pub-id pub-id-type="doi">10.1002/(SICI)1097-0142(19960501)77:9&lt;1836::AID-CNCR12&gt;3.0.CO;2-0</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Risinger JI, Barrett JC, Watson P et&#xA0;al (1996) Molecular genetic evidence of the occurrence of breast cancer as an integral tumor in patients with the hereditary nonpolyposis colorectal carcinoma syndrome. Cancer 9:1836&#x2013;1843 <pub-id pub-id-type="pmid">8646682</pub-id></citation>
      </ref>
      <ref id="CR80">
        <label>80.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scott</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>McPhillips</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Meldrum</surname>
              <given-names>CJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Hereditary nonpolyposis colorectal cancer in 95 families: differences and similarities between mutation-positive and mutation-negative kindreds</article-title>
          <source>Am J Hum Genet</source>
          <year>2001</year>
          <volume>1</volume>
          <fpage>118</fpage>
          <lpage>127</lpage>
          <pub-id pub-id-type="doi">10.1086/316942</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Scott RJ, McPhillips M, Meldrum CJ et&#xA0;al (2001) Hereditary nonpolyposis colorectal cancer in 95 families: differences and similarities between mutation-positive and mutation-negative kindreds. Am J Hum Genet 1:118&#x2013;127 <pub-id pub-id-type="pmid">11112663</pub-id></citation>
      </ref>
      <ref id="CR81">
        <label>81.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Westenend</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Schutte</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hoogmans</surname>
              <given-names>MM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Breast cancer in an MSH2 gene mutation carrier</article-title>
          <source>Hum Pathol</source>
          <year>2005</year>
          <volume>12</volume>
          <fpage>1322</fpage>
          <lpage>1326</lpage>
          <pub-id pub-id-type="doi">10.1016/j.humpath.2005.08.025</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Westenend PJ, Schutte R, Hoogmans MM et&#xA0;al (2005) Breast cancer in an MSH2 gene mutation carrier. Hum Pathol 12:1322&#x2013;1326 <pub-id pub-id-type="pmid">16311127</pub-id></citation>
      </ref>
      <ref id="CR82">
        <label>82.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Spagnoletti</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Pizzi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Galietta</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Loss of hMSH2 expression in primary breast cancer with p53 alterations</article-title>
          <source>Oncol Rep</source>
          <year>2004</year>
          <volume>4</volume>
          <fpage>845</fpage>
          <lpage>851</lpage>
        </citation>
        <citation citation-type="display-unstructured">Spagnoletti I, Pizzi C, Galietta A et&#xA0;al (2004) Loss of hMSH2 expression in primary breast cancer with p53 alterations. Oncol Rep 4:845&#x2013;851 <pub-id pub-id-type="pmid">15010883</pub-id></citation>
      </ref>
      <ref id="CR83">
        <label>83.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haerer</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>Jackson</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Evers</surname>
              <given-names>CG</given-names>
            </name>
          </person-group>
          <article-title>Ataxia-telangiectasia with gastric adenocarcinoma</article-title>
          <source>JAMA</source>
          <year>1969</year>
          <volume>10</volume>
          <fpage>1884</fpage>
          <lpage>1887</lpage>
          <pub-id pub-id-type="doi">10.1001/jama.210.10.1884</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Haerer AF, Jackson JF, Evers CG (1969) Ataxia-telangiectasia with gastric adenocarcinoma. JAMA 10:1884&#x2013;1887 <pub-id pub-id-type="pmid">4311128</pub-id></citation>
      </ref>
      <ref id="CR84">
        <label>84.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Watanabe</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hanazono</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Sogawa</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Stomach cancer of a 14-year-old boy with ataxia-telangiectasia</article-title>
          <source>Tohoku J Exp Med</source>
          <year>1977</year>
          <volume>2</volume>
          <fpage>127</fpage>
          <lpage>131</lpage>
        </citation>
        <citation citation-type="display-unstructured">Watanabe A, Hanazono H, Sogawa H et&#xA0;al (1977) Stomach cancer of a 14-year-old boy with ataxia-telangiectasia. Tohoku J Exp Med 2:127&#x2013;131 <pub-id pub-id-type="pmid">191957</pub-id></citation>
      </ref>
      <ref id="CR85">
        <label>85.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bigbee</surname>
              <given-names>WL</given-names>
            </name>
            <name>
              <surname>Langlois</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Swift</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Evidence for an elevated frequency of in&#xA0;vivo somatic cell mutations in ataxia telangiectasia</article-title>
          <source>Am J Hum Genet</source>
          <year>1989</year>
          <volume>3</volume>
          <fpage>402</fpage>
          <lpage>408</lpage>
        </citation>
        <citation citation-type="display-unstructured">Bigbee WL, Langlois RG, Swift M et&#xA0;al (1989) Evidence for an elevated frequency of in&#xA0;vivo somatic cell mutations in ataxia telangiectasia. Am J Hum Genet 3:402&#x2013;408 <pub-id pub-id-type="pmid">2916583</pub-id></citation>
      </ref>
      <ref id="CR86">
        <label>86.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thompson</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Duedal</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kirner</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cancer risks and mortality in heterozygous ATM mutation carriers</article-title>
          <source>J Natl Cancer Inst</source>
          <year>2005</year>
          <volume>11</volume>
          <fpage>813</fpage>
          <lpage>822</lpage>
        </citation>
        <citation citation-type="display-unstructured">Thompson D, Duedal S, Kirner J et&#xA0;al (2005) Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst 11:813&#x2013;822 <pub-id pub-id-type="pmid">15928302</pub-id></citation>
      </ref>
      <ref id="CR87">
        <label>87.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Milo</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Deutsch</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Zahavi</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Xeroderma pigmentosum with recurrent infiltrating ductal carcinoma of breast</article-title>
          <source>Postgrad Med J</source>
          <year>1994</year>
          <volume>821</volume>
          <fpage>240</fpage>
          <lpage>241</lpage>
        </citation>
        <citation citation-type="display-unstructured">Milo Y, Deutsch AA, Zahavi S et&#xA0;al (1994) Xeroderma pigmentosum with recurrent infiltrating ductal carcinoma of breast. Postgrad Med J 821:240&#x2013;241 <pub-id pub-id-type="pmid">8183768</pub-id></citation>
      </ref>
      <ref id="CR88">
        <label>88.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Puig</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Marti</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Matias-Guiu</surname>
              <given-names>X</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Gastric adenocarcinoma in a patient with xeroderma pigmentosum</article-title>
          <source>Br J Dermatol</source>
          <year>1985</year>
          <volume>5</volume>
          <fpage>632</fpage>
          <lpage>633</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2133.1985.tb02394.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Puig L, Marti R, Matias-Guiu X et&#xA0;al (1985) Gastric adenocarcinoma in a patient with xeroderma pigmentosum. Br J Dermatol 5:632&#x2013;633 <pub-id pub-id-type="pmid">4063200</pub-id></citation>
      </ref>
      <ref id="CR89">
        <label>89.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tsuchiya</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tomita</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ohno</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Werner&#x2019;s syndrome combined with quintuplicate malignant tumors: a case report and review of literature data</article-title>
          <source>Jpn J Clin Oncol</source>
          <year>1991</year>
          <volume>2</volume>
          <fpage>135</fpage>
          <lpage>142</lpage>
        </citation>
        <citation citation-type="display-unstructured">Tsuchiya H, Tomita K, Ohno M et&#xA0;al (1991) Werner&#x2019;s syndrome combined with quintuplicate malignant tumors: a case report and review of literature data. Jpn J Clin Oncol 2:135&#x2013;142 <pub-id pub-id-type="pmid">2067129</pub-id></citation>
      </ref>
      <ref id="CR90">
        <label>90.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wirtenberger</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Frank</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Hemminki</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Interaction of Werner and Bloom syndrome genes with p53 in familial breast cancer</article-title>
          <source>Carcinogenesis</source>
          <year>2006</year>
          <volume>8</volume>
          <fpage>1655</fpage>
          <lpage>1660</lpage>
        </citation>
        <citation citation-type="display-unstructured">Wirtenberger M, Frank B, Hemminki K et&#xA0;al (2006) Interaction of Werner and Bloom syndrome genes with p53 in familial breast cancer. Carcinogenesis 8:1655&#x2013;1660 <pub-id pub-id-type="pmid">16501249</pub-id></citation>
      </ref>
    </ref-list>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>DGC</term>
          <def>
            <p>diffuse gastric cancer</p>
          </def>
        </def-item>
        <def-item>
          <term>GC</term>
          <def>
            <p>gastric cancer</p>
          </def>
        </def-item>
        <def-item>
          <term>HDGC</term>
          <def>
            <p>hereditary diffuse gastric cancer</p>
          </def>
        </def-item>
        <def-item>
          <term>LBC</term>
          <def>
            <p>lobular breast cancer</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
  </back>
</article>
</pmc-articleset>
